1. In vivo monitoring of angiogenesis during tendon repair: a novel MRI-based technique in a rat patellar tendon model.

    Knee Surgery, Sports Traumatology, Arthroscopy 23(8):2433 (2015) PMID 24519623

    Recent in vivo studies were able to show the impairing effect of neoangiogenesis in degenerative tendon diseases. Clinical in vivo monitoring of angiogenesis in injured tendons therefore seems to be crucial for an accurate therapeutic approach. The aim of this study was to develop a novel magnet...
  2. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

    Cell 162(1):146 (2015) PMID 26140595

    KRAS is one of the most frequently mutated oncogenes in human cancer. Despite substantial efforts, no clinically applicable strategy has yet been developed to effectively treat KRAS-mutant tumors. Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell...
  3. Implantation of venous access devices under local anesthesia: patients' satisfaction with oral lorazepam.

    Patient Preference and Adherence 9:943 (2015) PMID 26185424 PMCID PMC4501160

    The aim of the study reported here was to evaluate patients' satisfaction with implantation of venous access devices under local anesthesia (LA) with and without additional oral sedation. A total of 77 patients were enrolled in the prospective descriptive study over a period of 6 months. Subcuta...
  4. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

    Clinical Cancer Research 20(13):3560 (2014) PMID 24780294

    The cutoff values currently used to categorize tumor response to therapy are neither biologically based nor tailored for measurement reproducibility with contemporary imaging modalities. Sources and magnitudes of discordance in response assessment in metastatic colorectal cancer (mCRC) are unkno...
  5. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

    Clinical Cancer Research 20(13):3560 (2014) PMID 24780294 PMCID PMC4337392

    The cutoff values currently used to categorize tumor response to therapy are neither biologically based nor tailored for measurement reproducibility with contemporary imaging modalities. Sources and magnitudes of discordance in response assessment in metastatic colorectal cancer (mCRC) are unkno...
  6. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

    Clinical Cancer Research 20(13):3560 (2014) PMID 24780294 PMCID PMC4337392

    The cutoff values currently used to categorize tumor response to therapy are neither biologically based nor tailored for measurement reproducibility with contemporary imaging modalities. Sources and magnitudes of discordance in response assessment in metastatic colorectal cancer (mCRC) are unkno...
  7. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

    Clinical Cancer Research 20(13):3560 (2014) PMID 24780294

    The cutoff values currently used to categorize tumor response to therapy are neither biologically based nor tailored for measurement reproducibility with contemporary imaging modalities. Sources and magnitudes of discordance in response assessment in metastatic colorectal cancer (mCRC) are unkno...
  8. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm.

    Clinical Cancer Research 20(13):3560 (2014) PMID 24780294

    The cutoff values currently used to categorize tumor response to therapy are neither biologically based nor tailored for measurement reproducibility with contemporary imaging modalities. Sources and magnitudes of discordance in response assessment in metastatic colorectal cancer (mCRC) are unkno...
  9. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

    Journal of Clinical Oncology 32(17):1776 (2014) PMID 24799482

    Positron emission tomography (PET) after chemotherapy can guide consolidating radiotherapy in advanced-stage Hodgkin lymphoma (HL). This analysis aims to improve outcome prediction by integrating additional criteria derived by computed tomography (CT). The analysis set consisted of 739 patients ...
  10. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

    Journal of Clinical Oncology 32(17):1776 (2014) PMID 24799482

    Positron emission tomography (PET) after chemotherapy can guide consolidating radiotherapy in advanced-stage Hodgkin lymphoma (HL). This analysis aims to improve outcome prediction by integrating additional criteria derived by computed tomography (CT). The analysis set consisted of 739 patients ...
  11. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

    Angiogenesis 17(1):235 (2014) PMID 24136410

    The fusion protein tTF-NGR consists of the extracellular domain of the thrombogenic human tissue factor (truncated tissue factor, tTF) and the peptide GNGRAHA (NGR), a ligand of the surface protein CD13 (aminopeptidase N), upregulated on endothelial cells of tumor vessels. tTF-NGR preferentially...
  12. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

    Angiogenesis 17(1):235 (2014) PMID 24136410

    The fusion protein tTF-NGR consists of the extracellular domain of the thrombogenic human tissue factor (truncated tissue factor, tTF) and the peptide GNGRAHA (NGR), a ligand of the surface protein CD13 (aminopeptidase N), upregulated on endothelial cells of tumor vessels. tTF-NGR preferentially...
  13. Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group

    Lung Cancer 82(2):190 (2013)

    Imaging of malignant pleural mesothelioma (MPM) is essential to the diagnosis, assessment, and monitoring of this disease. The complex morphology and growth pattern of MPM, however, create unique challenges for image acquisition and interpretation. These challenges have captured the at...
  14. Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.

    Lung Cancer 82(2):190 (2013) PMID 24018024

    Imaging of malignant pleural mesothelioma (MPM) is essential to the diagnosis, assessment, and monitoring of this disease. The complex morphology and growth pattern of MPM, however, create unique challenges for image acquisition and interpretation. These challenges have captured the attention of...
  15. Imaging in pleural mesothelioma: A review of the 11th International Conference of the International Mesothelioma Interest Group

    Lung Cancer 82(2):190 (2013) PMID 24018024

    Imaging of malignant pleural mesothelioma (MPM) is essential to the diagnosis, assessment, and monitoring of this disease. The complex morphology and growth pattern of MPM, however, create unique challenges for image acquisition and interpretation. These challenges have captured the at...
  16. Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.

    Molecular Imaging 12(7):1 (2013) PMID 23962676

    The aim of this study was to evaluate a robust magnetic resonance (MR) vessel size imaging (VSI) method for the noninvasive assessment of mean vessel size in solid tumors in a clinical dose range of ultrasmall superparamagnetic particles of iron oxide (USPIO). Therefore, USPIO-enhanced MR-VSI wa...
  17. Vessel size imaging (VSI) by robust magnetic resonance (MR) relaxometry: MR-VSI of solid tumors in correlation with immunohistology and intravital microscopy.

    Molecular Imaging 12(7):1 (2013) PMID 23962676

    The aim of this study was to evaluate a robust magnetic resonance (MR) vessel size imaging (VSI) method for the noninvasive assessment of mean vessel size in solid tumors in a clinical dose range of ultrasmall superparamagnetic particles of iron oxide (USPIO). Therefore, USPIO-enhanced MR-VSI wa...
  18. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.

    Radiology 268(1):254 (2013) PMID 23468578

    To retrospectively identify quantitative computed tomographic (CT) features that correlate with epidermal growth factor receptor (EGFR) mutation in surgically resected lung adenocarcinomas stratified by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society...
  19. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.

    Radiology 268(1):254 (2013) PMID 23468578

    To retrospectively identify quantitative computed tomographic (CT) features that correlate with epidermal growth factor receptor (EGFR) mutation in surgically resected lung adenocarcinomas stratified by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society...
  20. 1019 Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts

    Gastroenterology 142(5):S (2012)